Table 8.
Treatments in SARS CoV-2 patients with pneumonia.
| Treatment | Total n = 106 |
SARS CoV-2 and Pneumonia n = 26 |
SARS CoV-2 and Non-Pneumonia n = 80 |
Chi2
Test p |
|---|---|---|---|---|
| Remdesivir | 2 (1.9%) | 1 (3.8%) | 1 (1.3%) | 0.433 |
| Anticoagulant | 30 (28.3%) | 9 (34.6%) | 21 (26.3%) | 0.417 |
| Kaletra (lopinavir 80 mg and ritonavir 20 mg) |
20 (18.9%) | 12 (46.2%) | 7 (10.0%) | 0.001 |
| Dexamethasone | 24 (22.6%) | 15 (57.7%) | 9 (11.3%) | 0.001 |
| Antibiotic | 37 (34.9%) | 20 (76.9%) | 17 (21.3%) | 0.001 |
| Ceftriaxone | 27 (25.5%) | 14 (53.8%) | 13 (16.3%) | 0.001 |
| Augmentin | 4 (3.8%) | 1 (3.8%) | 3 (3.8%) | 0.982 |
| Clarithromycin | 8 (7.5%) | 5 (19.2%) | 3 (3.8%) | 0.017 |
| Azithromycin | 2 (1.9%) | 2 (7.7%) | 0 (0.0%) | 0.012 |
| Paracetamol | 84 (79.2%) | 21 (80.8%) | 63 (78.7%) | 0.824 |
| Codeine | 17 (16.0%) | 5 (19.2%) | 12 (15.0%) | 0.615 |
| Vitamins | 100 (94.3%) | 25 (96.2%) | 75 (93.8%) | 0.631 |
| Antihistamines | 6 (5.7%) | 2 (7.7%) | 4 (5.0%) | 0.617 |
Abbreviations: SARS CoV-2, Severe Acute Respiratory Syndrome-Corona Virus-2.